CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home Search
Result Type
Evidence Bundles
Product Line
Body Systems
Disease and Conditions
Target Population
Technologies, Therapies and Systems
Testing and Diagnostics
Publication Date
Clear all filters

Reports

We found 6858 result(s)

Dr. Luc Boileau

Published on: January 14, 2011
Result type: General Content

Member — Observer (Quebec) As a doctor trained at the Université de Sherbrooke and a specialist in public health, Dr. Luc Boileau holds a master’s in health administration from the Université de Montréal and a fellowship from the Canadian Health Services Research Foundation. In addition to his 25 years of clinical experience — particularly in...

ticagrelor (Brilinta)

Last Updated: October 10, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: ticagrelor
Indications: Prevention of atherothrombotic events with history of myocardial infarction

  • Brand Name: Brilinta
  • Manufacturer: AstraZeneca Canada Inc
  • Project Number: SR0474-000
  • Project Status: Complete
  • Submission Type: New Indication
Details

Secukinumab (Cosentyx)

Last Updated: January 21, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Secukinumab
Indications: Arthritis, psoriatic

  • Brand Name: Cosentyx
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0476-000
  • Project Status: Complete
  • Submission Type: New
Details

Sapropterin dihydrochloride (Kuvan)

Last Updated: January 4, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Sapropterin dihydrochloride
Indications: Phenylketonuria (PKU)

  • Brand Name: Kuvan
  • Manufacturer: BioMarin Pharmaceutical (Canada) Inc.
  • Project Number: SR0472-000
  • Project Status: Complete
  • Submission Type: Resubmission
Details